Loading
Cancer Cells and Metastasis / Cancer, Stress, Anesthesia, and Immune Response / Treatment of Major Depression · Journal article
Frontiers in Pharmacology · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study demonstrating that vortioxetine enhances gemcitabine efficacy in pancreatic cancer cell lines and xenograft models through reduced MAOB expression. The findings are hypothesis-generating and require clinical translation; they do not yet support human use.
Preclinical in vitro and in vivo (xenograft) mechanistic study. Pancreatic cancer cell lines and xenograft models; no human subjects enrolled.. Intervention: Vortioxetine alone and in combination with gemcitabine; MAOB gene knockdown. Compared with: Gemcitabine alone; control or wildtype cells/tumors.
Vortioxetine significantly enhanced gemcitabine inhibition of pancreatic cancer cell proliferation in vitro and tumor growth in xenograft models Combination treatment markedly promoted apoptosis, shown by increased cleaved PARP and cleaved caspase-3 Treatment suppressed cancer cell migration and invasion and reversed EMT, with upregulation of E-cadherin and downregulation of N-cadherin and Snail
No safety or tolerability data; no in vivo toxicology in animal models. Xenograft studies do not establish pharmacokinetics, bioavailability, or whether vortioxetine reaches tumors at active concentrations in living animals.
These findings do not yet support clinical use. Vortioxetine is an approved antidepressant; any proposal to repurpose it in combination with gemcitabine requires first-in-human translational studies and clinical efficacy trials in patients with pancreatic cancer.
Preclinical in vitro and xenograft study proposing a mechanism by which an existing drug may enhance chemotherapy, without clinical efficacy data or human evidence.
As stated by the source record.
These findings do not yet support clinical use. Vortioxetine is an approved antidepressant; any proposal to repurpose it in combination with gemcitabine requires first-in-human translational studies and clinical efficacy trials in patients with pancreatic cancer.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, largely owing to chemoresistance and frequent recurrence following gemcitabine-based therapy. This study investigated whether vortioxetine, a multimodal serotonin (5-HT) modulator, could enhance the antitumor efficacy of gemcitabine and explored the underlying molecular mechanisms. Methods The effects of vortioxetine alone and in combination with gemcitabine were evaluated in pancreatic cancer cells and xenograft models. Cell proliferation, apoptosis, migration, invasion, and epithelial-mesenchymal transition (EMT) were assessed using functional assays and relevant molecular markers. RNA sequencing was performed to identify potential molecular targets of vortioxetine, followed by molecular docking, thermal stability assays, and gene knockdown experiments for mechanistic validation. Results Vortioxetine significantly enhanced the inhibitory effects of gemcitabine on pancreatic cancer cell proliferation in vitro and tumor growth in xenograft models. The combination treatment markedly promoted apoptosis, as indicated by increased levels of cleaved poly(ADP-ribose) polymerase (PARP) and cleaved caspase-3. It also suppressed cancer cell migration and invasion and reversed EMT-related changes, as demonstrated by the upregulation of E-cadherin and downregulation of N-cadherin and Snail. RNA sequencing identified monoamine oxidase B (MAOB; EC 1.4.3.4) as a potential molecular target associated with vortioxetine treatment, which was further supported by molecular docking and thermal stability assays. Moreover, MAOB knockdown phenocopied the effects of vortioxetine by enhancing gemcitabine sensitivity and suppressing EMT-associated phenotypes. Discussion Vortioxetine potentiates the antitumor efficacy of gemcitabine against pancreatic cancer, with its effects associated with reduced MAOB expression, enhanced apoptosis, and suppression of EMT. These findings support further investigation of vortioxetine combined with gemcitabine as a potential therapeutic strategy for overcoming chemoresistance in pancreatic cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.